EdgarLookup

Mosaic ImmunoEngineering Inc. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Mosaic ImmunoEngineering Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-3459.6%
Return on Assets
Net income ÷ assets
-1x
Debt-to-Equity
Total liabilities ÷ equity

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($687.8K) Apr 15, 2026
FY2025 Dec 31, 2024 ($922.0K) Apr 15, 2026
FY2024 Dec 31, 2023 ($1.01M) Apr 15, 2025
FY2023 Dec 31, 2022 ($2.38M) Apr 15, 2024
FY2022 Dec 31, 2021 ($3.68M) Mar 2, 2023
FY2021 Dec 31, 2020 ($842.2K) Jan 26, 2022
FY2021 May 31, 2020 ($511) Jan 26, 2022
FY2020 May 31, 2019 ($798.5K) Aug 24, 2020
FY2019 May 31, 2018 ($1.21M) Aug 29, 2019
FY2018 May 31, 2017 ($45.4K) Aug 29, 2018

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($616.1K) Apr 15, 2026
FY2025 Dec 31, 2024 ($879.7K) Apr 15, 2026
FY2024 Dec 31, 2023 ($1.40M) Apr 15, 2025
FY2023 Dec 31, 2022 ($2.63M) Apr 15, 2024
FY2022 Dec 31, 2021 ($3.50M) Mar 2, 2023

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $64.0K Apr 15, 2026
FY2025 Dec 31, 2024 $183.9K Apr 15, 2026
FY2024 Dec 31, 2023 $435.4K Apr 15, 2025
FY2023 Dec 31, 2022 $1.05M Apr 15, 2024
FY2022 Dec 31, 2021 $1.46M Mar 2, 2023
FY2021 Dec 31, 2020 $342.7K Jan 26, 2022
FY2021 May 31, 2020 $0 Jan 26, 2022

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2020 May 31, 2020 $996.0K Aug 24, 2020
FY2020 May 31, 2019 $734.1K Aug 24, 2020
FY2019 May 31, 2018 $1.05M Aug 29, 2019
FY2018 May 31, 2017 $1.22M Aug 29, 2018
FY2017 May 31, 2016 $1.58M Aug 29, 2017
FY2016 May 31, 2015 $1.44M Aug 29, 2016
FY2015 May 31, 2014 $1.66M Aug 31, 2015
FY2014 May 31, 2013 $1.38M Aug 19, 2014
FY2013 May 31, 2012 $1.99M Aug 23, 2013
FY2012 May 31, 2011 $2.55M Aug 29, 2012

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($111.4K) Apr 15, 2026
FY2025 Dec 31, 2024 ($241.2K) Apr 15, 2026
FY2024 Dec 31, 2023 ($497.5K) Apr 15, 2025
FY2023 Dec 31, 2022 ($690.1K) Apr 15, 2024
FY2022 Dec 31, 2021 ($679.2K) Mar 2, 2023
FY2021 Dec 31, 2020 ($253.0K) Jan 26, 2022
FY2021 May 31, 2020 $500 Jan 26, 2022
FY2020 May 31, 2019 ($760.8K) Aug 24, 2020
FY2019 May 31, 2018 ($880.2K) Aug 29, 2019
FY2018 May 31, 2017 ($1.31M) Aug 29, 2018

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2019 May 31, 2019 $0 Aug 29, 2019
FY2019 May 31, 2018 $1.5K Aug 29, 2019
FY2018 May 31, 2017 $2.7K Aug 29, 2018
FY2017 May 31, 2016 $0 Aug 29, 2017
FY2016 May 31, 2015 $1.7K Aug 29, 2016
FY2015 May 31, 2014 $0 Aug 31, 2015
FY2014 May 31, 2013 $2.2K Aug 19, 2014
FY2013 May 31, 2012 $2.0K Aug 23, 2013
FY2012 May 31, 2011 $6.8K Aug 29, 2012

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $19.9K Apr 15, 2026
FY2025 Dec 31, 2024 $141.6K Apr 15, 2026
FY2024 Dec 31, 2023 $179.5K Apr 15, 2025
FY2023 Dec 31, 2022 $261.3K Apr 15, 2024
FY2022 Dec 31, 2021 $269.5K Mar 2, 2023
FY2021 Dec 31, 2020 $457.8K Jan 26, 2022
FY2020 May 31, 2020 $818.6K Aug 24, 2020
FY2020 May 31, 2019 $1.92M Aug 24, 2020
FY2019 May 31, 2018 $2.58M Aug 29, 2019
FY2018 May 31, 2017 $3.76M Aug 29, 2018

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $7.50M Apr 15, 2026
FY2025 Dec 31, 2024 $6.93M Apr 15, 2026
FY2024 Dec 31, 2023 $6.05M Apr 15, 2025
FY2023 Dec 31, 2022 $5.15M Apr 15, 2024
FY2022 Dec 31, 2021 $3.07M Mar 2, 2023
FY2021 Dec 31, 2020 $880.3K Jan 26, 2022
FY2020 May 31, 2020 $182.6K Aug 24, 2020
FY2020 May 31, 2019 $228.2K Aug 24, 2020
FY2019 May 31, 2018 $84.8K Aug 29, 2019
FY2018 May 31, 2017 $56.6K Aug 29, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($7.48M) Apr 15, 2026
FY2025 Dec 31, 2024 ($6.79M) Apr 15, 2026
FY2025 Dec 31, 2023 ($5.87M) Apr 15, 2026
FY2024 Dec 31, 2022 ($4.88M) Apr 15, 2025
FY2023 Dec 31, 2021 ($2.80M) Apr 15, 2024
FY2022 Dec 31, 2020 ($422.5K) Mar 2, 2023
FY2021 May 31, 2020 ($448) Jan 26, 2022
FY2021 Mar 31, 2020 $0 Jan 26, 2022
FY2020 May 31, 2019 $1.70M Aug 24, 2020
FY2020 May 31, 2018 $2.50M Aug 24, 2020

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($9.53M) Apr 15, 2026
FY2025 Dec 31, 2024 ($8.84M) Apr 15, 2026
FY2024 Dec 31, 2023 ($7.92M) Apr 15, 2025
FY2023 Dec 31, 2022 ($6.91M) Apr 15, 2024
FY2022 Dec 31, 2021 ($4.53M) Mar 2, 2023
FY2021 Dec 31, 2020 ($842.8K) Jan 26, 2022
FY2020 May 31, 2020 ($62.19M) Aug 24, 2020
FY2020 May 31, 2019 ($61.13M) Aug 24, 2020
FY2019 May 31, 2018 ($60.33M) Aug 29, 2019
FY2018 May 31, 2017 ($59.12M) Aug 29, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $3.6K Apr 15, 2026
FY2025 Dec 31, 2024 $115.0K Apr 15, 2026
FY2024 Dec 31, 2023 $156.2K Apr 15, 2025
FY2023 Dec 31, 2022 $220.6K Apr 15, 2024
FY2022 Dec 31, 2021 $226.1K Mar 2, 2023
FY2021 Dec 31, 2020 $352.7K Jan 26, 2022
FY2020 May 31, 2020 $571.9K Aug 24, 2020
FY2020 May 31, 2019 $787.1K Aug 24, 2020
FY2019 May 31, 2018 $2.30M Aug 29, 2019
FY2018 May 31, 2017 $979.6K Aug 29, 2018

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Apr 15, 2026
FY2025 Dec 31, 2024 0 Apr 15, 2026
FY2024 Dec 31, 2023 0 Apr 15, 2025
FY2023 Dec 31, 2022 0 Apr 15, 2024
FY2022 Dec 31, 2021 0 Mar 2, 2023
FY2021 Dec 31, 2020 (1) Jan 26, 2022
FY2021 May 31, 2020 0 Jan 26, 2022
FY2020 May 31, 2019 0 Aug 24, 2020
FY2019 May 31, 2018 0 Aug 29, 2019
FY2018 May 31, 2017 0 Aug 29, 2018

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Apr 15, 2026
FY2025 Dec 31, 2024 0 Apr 15, 2026
FY2024 Dec 31, 2023 0 Apr 15, 2025
FY2023 Dec 31, 2022 0 Apr 15, 2024
FY2022 Dec 31, 2021 0 Mar 2, 2023
FY2021 Dec 31, 2020 (1) Jan 26, 2022
FY2021 May 31, 2020 0 Jan 26, 2022
FY2020 May 31, 2019 0 Aug 24, 2020
FY2019 May 31, 2018 0 Aug 29, 2019
FY2018 May 31, 2017 0 Aug 29, 2018

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 7.24M Apr 15, 2026
FY2025 Dec 31, 2024 7.24M Apr 15, 2026
FY2024 Dec 31, 2023 7.24M Apr 15, 2025
FY2023 Dec 31, 2022 7.24M Apr 15, 2024
FY2022 Dec 31, 2021 7.24M Mar 2, 2023
FY2021 Dec 31, 2020 805,803 Jan 26, 2022
FY2020 May 31, 2020 401.39M Aug 24, 2020
FY2020 May 31, 2019 401.39M Aug 24, 2020
FY2019 May 31, 2018 401.39M Aug 29, 2019
FY2018 May 31, 2017 401.39M Aug 29, 2018